title: Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication.
abstract: The high efficacy of therapeutic cancer vaccines in preclinical studies has yet to be fully achieved in clinical trials. Tumor immune suppression is a critical factor that hampers the desired antitumor effect. Here, we analyzed the combined effect of a cancer vaccine and the receptor tyrosine kinase inhibitor sunitinib. Sunitinib was administered intraperitoneally, alone or in combination with intramuscular immunization using a viral vector based cancer vaccine composed of Semliki Forest virus replicon particles and encoding the oncoproteins E6 and E7 (SFVeE6,7) of human papilloma virus (HPV). We first demonstrated that treatment of tumor-bearing mice with sunitinib alone dose-dependently depleted myeloid-derived suppressor cells (MDSCs) in the tumor, spleen and in circulation. Concomitantly, the number of CD8+T cells increased 2-fold and, on the basis of CD69 expression, their activation status was greatly enhanced. The intrinsic immunosuppressive activity of residual MDSCs after sunitinib treatment was not changed in a dose-dependent fashion. We next combined sunitinib treatment with SFVeE6,7 immunization. This combined treatment resulted in a 1.5- and 3-fold increase of E7-specific cytotoxic T lymphocytes (CTLs) present within the circulation and tumor, respectively, as compared to immunization only. The ratio of E7-specific CTLs to MDSCs in blood thereby increased 10- to 20-fold and in tumors up to 12.5-fold. As a result, the combined treatment strongly enhanced the antitumor effect of the cancer vaccine. This study demonstrates that sunitinib creates a favorable microenvironment depleted of MDSCs and acts synergistically with a cancer vaccine resulting in enhanced levels of active tumor-antigen specific CTLs, thus changing the balance in favor of antitumor immunity.
authors.affiliation: Department of Medical Microbiology, Tumor Virology and Cancer Immunotherapy; University of Groningen; University Medical Center Groningen ; Groningen, the Netherlands.
authors.forename: Oana
authors.initials: O
authors.lastname: Draghiciu
authors.affiliation: Department of Gynecology; University of Groningen; University Medical Center Groningen ; Groningen, the Netherlands.
authors.forename: Hans W
authors.initials: HW
authors.lastname: Nijman
authors.affiliation: Department of Medical Microbiology, Tumor Virology and Cancer Immunotherapy; University of Groningen; University Medical Center Groningen ; Groningen, the Netherlands.
authors.forename: Baukje Nynke
authors.initials: BN
authors.lastname: Hoogeboom
authors.affiliation: Department of Medical Microbiology, Tumor Virology and Cancer Immunotherapy; University of Groningen; University Medical Center Groningen ; Groningen, the Netherlands.
authors.forename: Tjarko
authors.initials: T
authors.lastname: Meijerhof
authors.affiliation: Department of Medical Microbiology, Tumor Virology and Cancer Immunotherapy; University of Groningen; University Medical Center Groningen ; Groningen, the Netherlands.
authors.forename: Toos
authors.initials: T
authors.lastname: Daemen
keywords: ARG1, arginase-1; CTL, cytotoxic T lymphocyte; DC, dendritic cell; Flt3, Fms-like tyrosine kinase 3; HPV, human papilloma virus; MDSC, myeloid-derived suppressor cell; PBMC, peripheral blood mononuclear cell; Semliki Forest virus; TGFβ, transforming growth factor β; Treg, regulatory T cell; VEGF, vascular endothelial growth factor receptor.; cancer vaccine; iNOS, nitric oxide synthase; mRCC, metastatic renal cell carcinoma; myeloid-derived suppressor cells; rSFV, recombinant Semliki forest virus; sunitinib; suppressive factors